• After the 2023 closure of UK Cochrane review groups and Cochrane Skin’s move to Paris, which eczema reviews (EPO 2013, CHM 2013, supplements 2012, HDM 2015) are scheduled for update? (Cochrane)
• Will the FDA revisit the 2006 TCI boxed warning, as Health Canada and the UK have done, given PEER and the 2023 meta-analysis? (FDA)
• Why did the EMA restrict dupilumab to severe AD in 6 mo–11 y while the FDA allows moderate-to-severe — was it a filing or an efficacy-threshold decision? (European Medicines Agency)